Truist Securities Reiterates Buy on Cytokinetics, Maintains $86 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Srikripa Devarakonda has reiterated a Buy rating on Cytokinetics (NASDAQ:CYTK) and maintained an $86 price target.
April 08, 2024 | 3:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities reaffirms a Buy rating on Cytokinetics with an $86 price target.
The reiteration of a Buy rating and maintenance of a high price target by a reputable analyst like Srikripa Devarakonda from Truist Securities could positively influence investor sentiment towards Cytokinetics. This endorsement may lead to increased investor confidence in CYTK, potentially driving up its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100